Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00816023 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume
A Phase 2 study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 276
- Enrollment target
NCT00816023: Completed Phase 2 study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00816023 is a Phase 2 study that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 276 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00816023, a Phase 2 study, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
Interventions
- DRUG placebo
- DRUG ecallantide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
What the finished NCT00816023 record still lists
NCT00816023 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00816023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00816023 about?
NCT00816023 is a clinical study titled "A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume". The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
What is the current status of trial NCT00816023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2009-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00816023?
The interventions under investigation include: placebo (DRUG), ecallantide (DRUG).
Who is sponsoring clinical trial NCT00816023?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00816023's enrollment target sits among peer trials
276 202nd of 2000 higher than 1,798 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia